Skip to main content
Explore URMC
URMC / Research / Clinical Trials / Study Details

Leukemia (ALL): Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Research Question:
What are the good and/or bad effects of adding the drug blinatumomab to different doses of standard combinations of chemotherapy drugs? Can standard therapy drugs can be given at lower doses (when given with blinatumomab) in order to reduce overall side effects and be effective in treating ALL?

Basic Study Information

This study will have 2 groups: subjects who do not have the Philadelphia chromosome mutation (Ph-) and subjects who do have the mutation (Ph+). Treatments for the two groups will be different and are outlined below. In general, there are 3 main steps to all of the treatments. Induction/Re-Induction treatment is given first. It is a treatment given over a short period of time (usually only a few months) to get rid of as many of the leukemia cells as possible very quickly. Post-Remission treatment is given next. It is given to get rid of any leukemia cells that are left once your leukemia goes into remission and to make sure the leukemia cells don’t come back over a short period of time (usually only a few months). Maintenance treatment is given last. It is a lower dose treatment given over a long period of time (up to several years) to help keep the leukemia cells from coming back. Depending on which arm of the study you are on, Blinatumomab will be given as part of induction/re-induction or post-remission along with standard chemotherapy.

Location: Cancer Center
Study Web URL:
Study Reference #: CLEU-15006

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 276-4415

Additional Study Details

Learn More About These Conditions

More information about Acute lymphoblastic leukemia [ALL]

Return to Search